Why the study?
Does rivaroxaban combined with antiplatelet therapy reduce cardiovascular complications and mortality in patients with coronary heart disease?
Does rivaroxaban combined with antiplatelet therapy reduce cardiovascular complications and mortality in patients with coronary heart disease?
Adding low-dose rivaroxaban to antiplatelet therapy in patients with acute and chronic coronary heart disease improves cardiovascular outcomes and survival, despite an increased risk of bleeding.
Answers are grounded in this paper and cite their sources.
May support rivaroxaban addition in coronary disease despite bleeding risk; leaves open confirmation by randomized trials.
A review presented, of the novel scientific data, mostly the results of large clinical trials, witnessing on clinical efficacy and safety of rivaroxaban — the anticoagulant, selective blocker of Xa factor — in treatment of acute and chronic coronary heart disease. The mechanisms explained, of the drug influence on atherothrombosis, especially the specifics of dosages and its combination with other antithrombotic drugs in various clinical situations.
No takes yet. Share an insight, caveat, or question.
В. Н. Хирманов (2018) conducted a review in Coronary heart disease. Rivaroxaban vs. Standard antiplatelet therapy or placebo was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: